Genialis krasID

Products & Services

Information

First-in-class patient classifier predicts response and stratifies clinical benefit of KRAS inhibition. Genialis krasID is designed to predict and monitor drug response from the simplest preclinical models to intent-to-treat real world patient cohorts
GenialisGenialis is the RNA biomarker company. We are creating a world where healthcare delivers the best possible outcomes for patients, their families and communities. Genialis develops and validates clinically actionable biomarkers informed by the world’s most ethnographically diverse cancer data sets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. Genialis is trusted by pharma and diagnostics partners, and together, we are transforming medicine through data.

Log in